| Year |
Citation |
Score |
| 2019 |
Aird D, Teng T, Huang CL, Pazolli E, Banka D, Cheung-Ong K, Eifert C, Furman C, Wu ZJ, Seiler M, Buonamici S, Fekkes P, Karr C, Palacino J, Park E, et al. Sensitivity to splicing modulation of BCL2 family genes defines cancer therapeutic strategies for splicing modulators. Nature Communications. 10: 137. PMID 30635584 DOI: 10.1038/S41467-018-08150-5 |
0.427 |
|
| 2019 |
Aird D, Teng T, Huang C, Pazolli E, Banka D, Cheung-Ong K, Eifert C, Furman C, Wu J, Seiler M, Buonamici S, Fekkes P, Karr C, Palacino J, Park E, et al. Abstract 281: Sensitivity to splicing modulation of BCL2 family genes reveals cancer therapeutic strategies for splicing modulators Cancer Research. 79: 281-281. DOI: 10.1158/1538-7445.Sabcs18-281 |
0.42 |
|
| 2018 |
Seiler M, Yoshimi A, Darman R, Chan B, Keaney G, Thomas M, Agrawal AA, Caleb B, Csibi A, Sean E, Fekkes P, Karr C, Klimek V, Lai G, Lee L, ... ... Pazolli E, et al. H3B-8800, an orally available small-molecule splicing modulator, induces lethality in spliceosome-mutant cancers. Nature Medicine. PMID 29457796 DOI: 10.1038/Nm.4493 |
0.453 |
|
| 2018 |
Flanagan KC, Alspach E, Pazolli E, Parajuli S, Ren Q, Arthur LL, Tapia R, Stewart SA. c-Myb and C/EBPβ regulate OPN and other senescence-associated secretory phenotype factors. Oncotarget. 9: 21-36. PMID 29416593 DOI: 10.18632/Oncotarget.22940 |
0.575 |
|
| 2017 |
Buonamici S, Yoshimi A, Thomas M, Seiler M, Chan B, Caleb B, Csibi F, Darman R, Fekkes P, Karr C, Keaney G, Kim A, Klimek V, Kumar P, Kunii K, ... ... Pazolli E, et al. Abstract 1185: H3B-8800, a novel orally available SF3b modulator, shows preclinical efficacy across spliceosome mutant cancers Cancer Research. 77: 1185-1185. DOI: 10.1158/1538-7445.Am2017-1185 |
0.496 |
|
| 2016 |
Weir HM, Bradbury RH, Lawson M, Rabow AA, Buttar D, Callis RJ, Curwen JO, de Almeida C, Ballard P, Hulse M, Donald CS, Feron LJ, Karoutchi G, MacFaul P, Moss T, ... ... Pazolli E, et al. AZD9496: An oral estrogen receptor inhibitor that blocks the growth of ER-positive and ESR1 mutant breast tumours in preclinical models. Cancer Research. PMID 27020862 DOI: 10.1158/0008-5472.Can-15-2357 |
0.373 |
|
| 2016 |
Buonamici S, Yoshimi A, Thomas M, Seiler M, Chan B, Caleb B, Darman R, Fekkes P, Karr C, Keaney GF, Klimek VM, Kunii K, Lee L, Lee SC, Liu X, ... ... Pazolli E, et al. H3B-8800, an Orally Bioavailable Modulator of the SF3b Complex, Shows Efficacy in Spliceosome-Mutant Myeloid Malignancies Blood. 128: 966-966. DOI: 10.1182/Blood.V128.22.966.966 |
0.446 |
|
| 2015 |
Buonamici S, Darman R, Perino S, Agrawal A, Peng S, Seiler M, Lim KH, Bhavsar EB, Feala J, Obeng EA, Bailey S, Chan B, Fekkes P, Keaney GF, Kumar P, ... ... Pazolli E, et al. Heterozygous Hotspot SF3B1 Mutations Found in Myelodysplastic Syndromes Downregulate Genes Involved in Differentiation of Erythroid Cells Blood. 126: 1643-1643. DOI: 10.1182/Blood.V126.23.1643.1643 |
0.373 |
|
| 2015 |
Park ES, Aicher M, Aird D, Buonamici S, Chan B, Eifert C, Fekkes P, Furman C, Gerard B, Karr C, Keaney G, Kunii K, Lee L, Pazolli E, Prajapati S, et al. Abstract 2941: Targeting MCL1-dependent cancers through RNA splicing modulation Cancer Research. 75: 2941-2941. DOI: 10.1158/1538-7445.Am2015-2941 |
0.45 |
|
| 2015 |
Aird D, Pazolli E, Furman C, Lee L, Kunii K, Park ES, Karr C, Chan B, Aicher M, Buonamici S, Wang JY, Feala J, Yu L, Warmuth M, Smith P, et al. Abstract C8: Targeting MCL1-dependent cancers with SF3B splicing modulators Molecular Cancer Therapeutics. 14. DOI: 10.1158/1535-7163.Targ-15-C8 |
0.452 |
|
| 2015 |
Darman RB, Perino SA, Seiler M, Peng S, Feala J, Fekkes P, Keaney GF, Kunii K, Lee L, Lim KH, Oda Y, Myint K, Obeng EA, Pazolli E, Park ES, et al. Abstract B125: Mutant SF3B1 downregulates proteins involved in differentiation, including ABCB7 Molecular Cancer Therapeutics. 14. DOI: 10.1158/1535-7163.Targ-15-B125 |
0.463 |
|
| 2014 |
Alspach E, Flanagan KC, Luo X, Ruhland MK, Huang H, Pazolli E, Donlin MJ, Marsh T, Piwnica-Worms D, Monahan J, Novack DV, McAllister SS, Stewart SA. p38MAPK plays a crucial role in stromal-mediated tumorigenesis. Cancer Discovery. 4: 716-29. PMID 24670723 DOI: 10.1158/2159-8290.Cd-13-0743 |
0.584 |
|
| 2013 |
Weir H, Nardone A, Lawson M, Rowlinson R, Hulse M, Powell S, Callis R, Walker G, Curwen J, Wilson Z, Bradbury R, Rabow A, Savi Cd, Pazolli E, Reavey N, et al. Abstract P5-09-20: Development of a novel selective estrogen receptor down-regulator which shows efficacy in pre-clinical models of endocrine resistance Cancer Research. 73. DOI: 10.1158/0008-5472.Sabcs13-P5-09-20 |
0.353 |
|
| 2012 |
Pazolli E, Alspach E, Milczarek A, Prior J, Piwnica-Worms D, Stewart SA. Chromatin remodeling underlies the senescence-associated secretory phenotype of tumor stromal fibroblasts that supports cancer progression. Cancer Research. 72: 2251-61. PMID 22422937 DOI: 10.1158/0008-5472.Can-11-3386 |
0.586 |
|
| 2011 |
Luo X, Ruhland MK, Pazolli E, Lind AC, Stewart SA. Osteopontin stimulates preneoplastic cellular proliferation through activation of the MAPK pathway. Molecular Cancer Research : McR. 9: 1018-29. PMID 21673011 DOI: 10.1158/1541-7786.Mcr-10-0472 |
0.613 |
|
| 2009 |
Pazolli E, Luo X, Brehm S, Carbery K, Chung JJ, Prior JL, Doherty J, Demehri S, Salavaggione L, Piwnica-Worms D, Stewart SA. Senescent stromal-derived osteopontin promotes preneoplastic cell growth. Cancer Research. 69: 1230-9. PMID 19155301 DOI: 10.1158/0008-5472.Can-08-2970 |
0.619 |
|
| 2008 |
Pazolli E, Stewart SA. Senescence: the good the bad and the dysfunctional. Current Opinion in Genetics & Development. 18: 42-7. PMID 18262406 DOI: 10.1016/J.Gde.2007.12.002 |
0.588 |
|
| Show low-probability matches. |